AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
AZD7325 Multiple Ascending Dose Study
- Conditions
- Healthy Volunteer
- Interventions
- Drug: AZD7325
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00681915
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Retrospective Survey for Patients With Hypertension and Diabetes Mellitus
- Conditions
- Hypertension
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT00681278
- Locations
- 🇰🇷
Research Site, Wonju, Korea, Republic of
Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France
- Conditions
- Gastroesophageal Reflux
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2008-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2500
- Registration Number
- NCT00681837
- Locations
- 🇨🇳
Research Site, Wenzhou, Zhejiang, China
Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT00681720
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.
- Conditions
- Diabetes
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4027
- Registration Number
- NCT00681850
- Locations
- 🇬🇧
Research Site, Westbury, United Kingdom
Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT00680745
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Adherence in Adolescents and Children Treated on Quetiapine
- Conditions
- Psychosis
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00680888
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
- Conditions
- Ovarian CarcinomaBreast Cancer
- Interventions
- Drug: AZD2281
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT00679783
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
- Conditions
- DyslipidemiaKidney Disease
- Interventions
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT00680017
- Locations
- 🇺🇸
Site Reference ID/Investigator# 8095, Philadelphia, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 22812, Dallas, Texas, United States
🇺🇸Site Reference ID/Investigator# 8136, Atlanta, Georgia, United States
Statins and Risk of Myocardial Infarction in Real Life in France
- Conditions
- Myocardial Infarction
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13171
- Registration Number
- NCT00679575
- Locations
- 🇫🇷
Research Site, Villefranche de Rouergue, France